Comparative glycoprofiling of HIV gp120 immunogens by capillary electrophoresis and MALDI mass spectrometry.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07

Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem (1990) 8.98

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11

Toward an AIDS vaccine. Science (2008) 4.83

Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature (2007) 3.01

Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics (2009) 2.93

Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses (1992) 2.52

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol (2005) 1.98

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90

Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res (2008) 1.73

GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics (2008) 1.64

Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem (2010) 1.48

UniCarbKB: building a knowledge platform for glycoproteomics. Nucleic Acids Res (2013) 1.40

Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol Chem (2012) 1.25

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol (2012) 1.24

Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol (2010) 1.22

Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res (2007) 1.19

On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. Anal Chem (2008) 1.14

Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine (2009) 1.04

Differential expression of LacdiNAc sequences (GalNAc beta 1-4GlcNAc-R) in glycoproteins synthesized by Chinese hamster ovary and human 293 cells. Glycobiology (1997) 0.93

Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res (2007) 0.91

Fast sequencing of oligosaccharides: the reagent-array analysis method. Proc Natl Acad Sci U S A (1992) 0.89

Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One (2012) 0.88

Effect of the quantity and linkage position of mannose (alpha 1,2) residues in capillary gel electrophoresis of high-mannose-type oligosaccharides. Anal Biochem (1996) 0.85

Influence of molecular configuration and conformation on the electromigration of oligosaccharides in narrow bore capillaries. Electrophoresis (2012) 0.80